WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H464991
CAS#: 1215711-91-3
Description: AMK is an active metabolite of the neurohormone melatonin. It is formed from melatonin via the metabolic intermediate AFMK that is then deformylated by catalase or formamidase. AMK scavenges singlet oxygen in vitro when used at a concentration of 200 µM. It inhibits the epinephrine- and arachidonic acid-induced production of prostaglandin E2 (PGE2) and PGD2 in ovine seminal vesicle microsomes in a concentration- and time-dependent manner, as well as LPS-induced increases in COX-2 levels in RAW 264.7 macrophages when used at a concentration of 500 µM. AMK (20 mg/kg) decreases MPTP-induced increases in lipid peroxidation in the cytosol and mitochondria from substantia nigra and striatum in a mouse model of MPTP-induced Parkinson’s disease.
Hodoodo Cat#: H464991
Name: AMK HCl
CAS#: 1215711-91-3
Chemical Formula: C12H17ClN2O3
Exact Mass: 272.09
Molecular Weight: 272.729
Elemental Analysis: C, 52.85; H, 6.28; Cl, 13.00; N, 10.27; O, 17.60
Synonym: AMK HCl; AMK Hydrochloride; amikacin
IUPAC/Chemical Name: N-(3-(2-amino-5-methoxyphenyl)-3-oxopropyl)acetamide hydrochloride
InChi Key: JMBYMENFYWCJRD-UHFFFAOYSA-N
InChi Code: InChI=1S/C12H16N2O3.ClH/c1-8(15)14-6-5-12(16)10-7-9(17-2)3-4-11(10)13;/h3-4,7H,5-6,13H2,1-2H3,(H,14,15);1H
SMILES Code: O=C(NCCC(C1=CC(OC)=CC=C1N)=O)C.Cl
Appearance: Solid powder
Purity: >95% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 272.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Ramirez MS, Tolmasky ME. Amikacin: Uses, Resistance, and Prospects for Inhibition. Molecules. 2017 Dec 19;22(12):2267. doi: 10.3390/molecules22122267. PMID: 29257114; PMCID: PMC5889950.
2: Kato H, Hamada Y. Amikacin Therapy in Japanese Pediatric Patients: Narrative Review. Int J Environ Res Public Health. 2022 Feb 10;19(4):1972. doi: 10.3390/ijerph19041972. PMID: 35206156; PMCID: PMC8871704.
3: Jenkins A, Thomson AH, Brown NM, Semple Y, Sluman C, MacGowan A, Lovering AM, Wiffen PJ; (BSAC Working Party on Therapeutic Drug Monitoring). Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. J Antimicrob Chemother. 2016 Oct;71(10):2754-9. doi: 10.1093/jac/dkw250. Epub 2016 Jul 11. PMID: 27494904.
4: Amikacin. Tuberculosis (Edinb). 2008 Mar;88(2):87-8. doi: 10.1016/S1472-9792(08)70003-9. PMID: 18486037.
5: Meyer RD. Amikacin. Ann Intern Med. 1981 Sep;95(3):328-32. doi: 10.7326/0003-4819-95-3-328. PMID: 7023310.
6: Marsot A, Guilhaumou R, Riff C, Blin O. Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies. Clin Pharmacokinet. 2017 Feb;56(2):127-138. doi: 10.1007/s40262-016-0428-x. PMID: 27324191.
7: Price KA, Chudzik GM. Amikacin. Lancet. 1977 Sep 24;2(8039):659-60. doi: 10.1016/s0140-6736(77)92523-5. PMID: 71471.
8: Gleckman R. Amikacin. Am Fam Physician. 1976 Dec;14(6):75. PMID: 998471.
9: Ristuccia AM, Cunha BA. An overview of amikacin. Ther Drug Monit. 1985;7(1):12-25. doi: 10.1097/00007691-198503000-00003. PMID: 3887667.
10: Maxwell A, Ghate V, Aranjani J, Lewis S. Breaking the barriers for the delivery of amikacin: Challenges, strategies, and opportunities. Life Sci. 2021 Nov 1;284:119883. doi: 10.1016/j.lfs.2021.119883. Epub 2021 Aug 11. PMID: 34390724.
11: Shirley M. Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease. Drugs. 2019 Apr;79(5):555-562. doi: 10.1007/s40265-019-01095-z. Erratum in: Drugs. 2019 Apr 3;: PMID: 30877642; PMCID: PMC6445814.
12: Smits A, Kulo A, van den Anker J, Allegaert K. The amikacin research program: a stepwise approach to validate dosing regimens in neonates. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):157-166. doi: 10.1080/17425255.2017.1234606. Epub 2016 Sep 21. PMID: 27623706.
13: Raut A, Sharma D, Suvarna V. A Status Update on Pharmaceutical Analytical Methods of Aminoglycoside Antibiotic: Amikacin. Crit Rev Anal Chem. 2022;52(2):375-391. doi: 10.1080/10408347.2020.1803042. Epub 2020 Aug 11. PMID: 32781828.
14: Torres A, Motos A, Battaglini D, Li Bassi G. Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects. Crit Care. 2018 Dec 17;22(1):343. doi: 10.1186/s13054-018-1958-4. PMID: 30558658; PMCID: PMC6297966.
15: Hefelfinger DC. Amikacin sulfate. JAMA. 1978 Mar 6;239(10):930-1. doi: 10.1001/jama.1978.03280370026016. PMID: 628036.
16: De Rosa FG, Roberts JA. Amikacin dosing in the ICU: we now know more, but still not enough…. Intensive Care Med. 2014 Jul;40(7):1033-5. doi: 10.1007/s00134-014-3308-6. Epub 2014 May 10. PMID: 24817029.
17: Amikacin. Med Lett Drugs Ther. 1976 Nov 5;18(23):97-8. PMID: 979911.
18: Alizadeh M, Amiri M, Bezaatpour A. Indirect Determination of Amikacin by Gold Nanoparticles as Redox Probe. Curr Drug Deliv. 2021;18(6):761-769. doi: 10.2174/1567201817666200719005919. PMID: 32682378.
19: Rodrigues D, Baldissera GS, Mathos D, Sartori A, Zavascki AP, Rigatto MH. Amikacin for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: clinical efficacy and toxicity. Braz J Microbiol. 2021 Dec;52(4):1913-1919. doi: 10.1007/s42770-021-00551-x. Epub 2021 Jun 30. PMID: 34191252; PMCID: PMC8578526.
20: Pien FD, Ho PW. Antimicrobial spectrum, pharmacology, adverse effects, and therapeutic use of amikacin sulfate. Am J Hosp Pharm. 1981 Jul;38(7):981-9. PMID: 7020413.
